Work

Modified Long-Acting UCN2 Promotes Fat Mass Loss While Preserving Skeletal Muscle Mass and Function in Mouse Models of Pharmacological Weight Loss and Sarcopenic Obesity

Year: 2026
Type: preprint
Abstract: No approved pharmacotherapy simultaneously reduces excess adiposity and preserves skeletal muscle mass and function. Such an agent would have two distinct applications: improvement of the quality of pharmacological weight loss and treatment of sarcopenic obesity. Urocortin 2 (UCN2) and its receptor corticotropin-releasing hormone receptor 2 (CRHR2) are highly expressed in skeletal muscle, where they regulate hypertrophy and metabolism. Here we show that a modified long-acting acylated UCN2 peptide reduces fat mass while preserving muscle mass and enhancing function across distinct mouse models. Pair-feeding showed these effects were independent of reduced food intake. Combined with the GLP-1 receptor agonist semaglutide or the GIP/GLP-1/glucagon triple agonist retatrutide, UCN2 produced the greatest magnitude of fat loss while preserving lean and muscle mass and increasing in vivo force production, and this gain persisted 4 weeks after dosing stopped. UCN2 increased energy expenditure, prevented the adaptive fall in expenditure caused by reduced food intake, and promoted whole-body fatty acid oxidation. In a sarcopenic obese mouse model, UCN2 reduced fat mass while increasing muscle mass, muscle function, and myofibrillar protein synthesis. These findings identify UCN2-CRHR2 signaling as a strategy to uncouple fat loss from muscle loss, both as a standalone therapy for sarcopenic obesity and as a combination partner with incretins.
Language: English
Open Access status: green
OpenAlex ID: W7236722257
Cites: 39
Cited by:
Related to: 10